Ascendis Pharma A/S (NASDAQ:ASND) Price Target Raised to $207.00

Ascendis Pharma A/S (NASDAQ:ASND) had its target price raised by Citigroup from $178.00 to $207.00 in a research report released on Tuesday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other equities research analysts also recently commented on the company. JPMorgan Chase & Co. decreased their target price on Ascendis Pharma A/S from $174.00 to $165.00 and set an overweight rating for the company in a report on Wednesday, September 4th. Bank of America lifted their price objective on shares of Ascendis Pharma A/S from $165.00 to $175.00 and gave the company a buy rating in a research note on Wednesday, September 4th. StockNews.com upgraded shares of Ascendis Pharma A/S from a sell rating to a hold rating in a research note on Thursday, September 5th. Oppenheimer restated an outperform rating and set a $190.00 target price (up from $180.00) on shares of Ascendis Pharma A/S in a research report on Tuesday. Finally, Jefferies Financial Group upped their price target on shares of Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a buy rating in a report on Tuesday, August 13th. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of Moderate Buy and a consensus price target of $193.77.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $153.43 on Tuesday. The stock has a 50-day moving average of $132.94 and a two-hundred day moving average of $136.52. The stock has a market cap of $8.93 billion, a P/E ratio of -15.49 and a beta of 0.63. Ascendis Pharma A/S has a one year low of $85.29 and a one year high of $161.00.

Institutional Investors Weigh In On Ascendis Pharma A/S

A number of institutional investors have recently modified their holdings of ASND. Private Ocean LLC acquired a new position in Ascendis Pharma A/S in the 1st quarter worth about $36,000. Quadrant Capital Group LLC increased its position in shares of Ascendis Pharma A/S by 90.4% in the fourth quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock worth $42,000 after buying an additional 91 shares during the period. GAMMA Investing LLC lifted its position in shares of Ascendis Pharma A/S by 52.0% during the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 102 shares in the last quarter. Finally, Barometer Capital Management Inc. acquired a new stake in Ascendis Pharma A/S in the 4th quarter valued at $126,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.